RU2238744C2 - Method for treating chronic purulent otitis media in children - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: it is necessary to rinse the cavity of middle ear with distilled water, introduce there a biostimulating "Actoinvit" serum activated with gamma-irradiation and diluted in distilled water at 1:20 ratio, correspondingly till filling the cavitary volume. Serum should be introduced into the cavity of patient's middle ear twice daily.

EFFECT: higher efficiency of therapy.

2 ex

Description

The invention relates to medicine, namely, otorhinolaryngology.

The problem of treating patients with chronic purulent otitis media is still very relevant, especially in childhood, due to the anatomical and physiological characteristics of the child's body. In addition, in recent years, some features have been revealed in the etiology, pathogenesis, and clinical course of chronic suppurative otitis media in children. In this connection, well-known therapeutic agents are often not effective enough.

Currently, several methods are known for the conservative treatment of chronic suppurative otitis media in children using topical application of various liquid medications:

Antibiotics, which often cause allergic reactions (especially in children), sharply suppress immunity, and also contribute to the appearance of antibiotic-resistant microflora (2); however, the most negative effect of antibiotics, to which the microflora is sensitive (neomycin, streptomycin, gentamicin, etc.), is ototoxic, which often leads not only to a decrease in auditory function, but also to its complete loss.

Proteolytic enzymes such as trypsin, chymotrepsin (4), the significant disadvantages of which are the duration of treatment, frequent allergic reactions, and limited action.

Hormones whose disadvantages are the duration of treatment (20-30 days), suppression of immunity and non-specific resistance factor (1).

Currently, the protective role of leukocytes and plasma components in various inflammatory diseases, including the ear, is known. However, treatment with autoserum in children is not possible, because receiving autoserum requires a daily intake of 10-15 ml of blood from the cubital vein, which is naturally completely excluded. In addition, after each administration of autoserum, repeated washing of the middle ear cavity is required, which is traumatic for the child (4).

The prototype of this invention is the local use of donor (parent, single-group) blood plasma in the treatment of chronic purulent otitis media in children (3). However, this method of treatment is acceptable in the presence of relatively large perforations in the eardrum, laborious (the procedure is repeated 4 times a day), while plasma can be used only during the day, since almost all anti-inflammatory factors lose their activity in 24 hours.

The object of the invention is a new method for the treatment of children suffering from chronic suppurative otitis media, namely the local use of biostimulating serum “Actoinvit” (BSA).

The aim of the invention is to increase the effectiveness of treatment of children with chronic purulent otitis media, and the prevention of exacerbation of this disease.

This goal is achieved by the fact that in the method of treating children with chronic purulent otitis media, including the introduction through the perforation (regardless of its size) of a liquid drug, biologically active serum is used, obtained from the blood of healthy and young donors and who underwent special functional training, activated gamma -exposure. Daily administration of BSA is carried out twice with preliminary washing of the tympanic cavity with distilled water.

The method is as follows. 1 g of dry biostimulating serum Actoinvit is diluted in 20 ml of distilled water. 1.5-2.0 ml of BSA solution is injected into the middle ear cavity washed with distilled water through a perforation and this procedure is repeated twice with an interval of 4-5 hours. The course of treatment is usually from 3 to 7 days.

The advantage of this method is a sharp increase in the effectiveness of the treatment of chronic purulent otitis media in children due to components that accelerate the resolution of inflammation, significantly increase the phagocytic activity of neutrophils. This is a long-acting substance.

The method is applied to 15 children with chronic purulent otitis media, aged 4.5 to 14 years.

Example 1. B. R., 7 years old (medical history No. 20209), was admitted to the hospital with a diagnosis of exacerbation of bilateral chronic purulent otitis media (epimesotympanitis on the right and epithympanitis on the left), the condition after anthromastoidectomy on both sides. With this disease, the child suffers from 4.5 years. In 1999, an anthromastoidectomy was performed on the right. In 2001 - an anthromastoidectomy on the left. Conducted antibacterial, restorative, vitamin therapy with the participation of physiotherapeutic methods of exposure was accompanied by a short-term positive clinical effect (from 4 to 6 months), and then relapses of the disease (suppuration from the ear, headache, increased fatigue, hyperesthesia in the behind the ear area) were again detected. Upon admission to the hospital, Actoinvit was treated with biostimulating serum. Daily, according to the scheme, BSA was administered transtimpanially from both sides. On the 4th day, suppuration from the ears stopped, was discharged from the hospital on the 10th day. During the subsequent follow-up examination (1 year), the purulent-inflammatory process in the middle ear cavity on both sides did not resume.

Example 2. B-th L., 13 years old (medical history No. 19242), was admitted to the hospital with a diagnosis of exacerbation of left-sided chronic purulent epimesotympanitis, right-sided chronic mesotympanitis (without exacerbation). Sick for 5 years. Repeatedly treated on an outpatient and inpatient basis (antibiotics, proteolytic enzymes, physiotherapy). However, remissions were short-lived. The course of BSA treatment was 5 days. Throughout the follow-up examination, the process in the ear did not resume.

LIST OF REFERENCES

1. Lopatin A.S. The principles of general and local steroid therapy in the treatment of polypous rhinosinitis // Russian rhinology. - 1996. - No. 2-3. - S.31.

2. Pinegin B.V., Latysheva T.V. Immunodeficiency states: the possibility of using immunomodulators // Attending physician. - 2001. - No. 3. - S. 48.

3. Skryabin A.S., Lazarev V.N., Ivoylov A.Yu. A method for the treatment of chronic suppurative otitis media. Patent of the Russian Federation No. 2033166 dated 04/20/1995

4.Skryabin A.S., Fedorova O.K. A method for the treatment of chronic suppurative otitis media. Copyright certificate No. 1560199. - 1990

Claims (1)

A method for the treatment of chronic purulent otitis media in children, including the introduction of a blood preparation into the cavity of the middle ear to fill its volume and preliminary washing of the cavity, characterized in that the preliminary washing of the cavity is carried out with distilled water, and the actinvit activated biostimulating serum is used as the blood preparation gamma irradiation and diluted in distilled water in a ratio of 1:20, respectively, which is injected into the middle ear cavity twice a day.